Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Gastrointestinal Neoplasms 2Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 627pembrolizumab 506Paclitaxel 455Gemcitabine 439Carboplatin 438Cisplatin 421Radiotherapy 382fludarabine 368Nivolumab 340Docetaxel 278Bevacizumab 276Irinotecan 258Magnetic Resonance Spectroscopy 246Fluorouracil 229Dexamethasone 225Specimen Handling 224Capecitabine 218Rituximab 206Oxaliplatin 201Cytarabine 201Biopsy 198Temozolomide 197Ipilimumab 197fludarabine phosphate 195Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 174Injections 171Cetuximab 171

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Interventional × CGX1321 × Clear all
NCT02675946 2022-01-26

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Curegenix Inc.

Phase 1 Unknown
72 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

NCT03507998 2020-07-24

Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors

Curegenix Inc.

Phase 1 Unknown
39 enrolled
Gastrointestinal

Bile Duct Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡